News

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine ...
(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In t ...
The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.
Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...
A fter just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics Evaluation and Research (CBER).
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
I believe the sentiment around Moderna began to go from bearish to a mixed condition in June, after the company received FDA approval for their next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283).
Dupixent (dupilumab) Interleukin-4 receptor alpha antagonist Treatment of adult patients with bullous pemphigoid. Dupixent Gains Approval for Bullous Pemphigoid mNexspike (COVID-19 vaccine ...
Those limits match the terms FDA recently approved for Novavax’s shot, Nuvaxovid and Moderna’s mNexspike.